VSTM Verastem, Inc. Stock Quote

VSTM [NASD]

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	1.50%	Shs Outstand	169.51M	Perf Week	-9.09%
Market Cap	371.80M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	2.03%	Shs Float	157.75M	Perf Month	-3.51%
Income	-86.60M	PEG	-	EPS next Q	-0.09	Inst Own	45.40%	Short Float	4.50%	Perf Quarter	80.33%
Sales	91.60M	P/S	4.06	EPS this Y	-79.40%	Inst Trans	0.84%	Short Ratio	1.99	Perf Half Y	59.42%
Book/sh	0.77	P/B	2.86	EPS next Y	27.50%	ROA	-45.00%	Target Price	-	Perf Year	13.40%
Cash/sh	-	P/C	-	EPS next 5Y	1.74%	ROE	-92.60%	52W Range	1.08 - 4.67	Perf YTD	3.29%
Dividend	-	P/FCF	-	EPS past 5Y	0.70%	ROI	-119.40%	52W High	-52.89%	Beta	1.05
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	63.70%	52W Low	103.70%	ATR	0.15
Employees	135	Current Ratio	5.00	Sales Q/Q	773.30%	Oper. Margin	-71.90%	RSI (14)	47.63	Volatility	6.05% 5.99%
Optionable	Yes	Debt/Eq	0.44	EPS Q/Q	119.10%	Profit Margin	-94.60%	Rel Volume	0.65	Prev Close	2.19
Shortable	Yes	LT Debt/Eq	0.36	Earnings	Nov 09 AMC	Payout	-	Avg Volume	3.57M	Price	2.20
Recom	2.30	SMA20	-4.49%	SMA50	6.57%	SMA200	24.12%	Volume	2,308,595	Change	0.46%

Jun-20-19

Downgrade

BTIG Research

Buy → Neutral

May-10-19

Downgrade

Raymond James

Outperform → Mkt Perform

Jul-13-18

Initiated

BTIG Research

Buy

$17

May-02-18

Initiated

Seaport Global Securities

Buy

$14

Mar-08-18

Initiated

B. Riley FBR, Inc.

Buy

$15

Sep-07-17

Reiterated

H.C. Wainwright

Buy

$6.50 → $10

Apr-13-17

Initiated

Oppenheimer

Outperform

Mar-24-17

Reiterated

H.C. Wainwright

Buy

$5 → $6.50

Sep-29-15

Downgrade

Raymond James

Strong Buy → Outperform

Sep-29-15

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Sep-29-15

Downgrade

Jefferies

Buy → Hold

Sep-29-15

Downgrade

Cantor Fitzgerald

Buy → Hold

Sep-28-15

Downgrade

ROTH Capital

Buy → Neutral

$23 → $2

Sep-28-15

Downgrade

Mizuho

Buy → Neutral

$21 → $2

Sep-09-15

Initiated

Raymond James

Strong Buy

May-12-15

Reiterated

UBS

Buy

$30 → $24

Apr-08-15

Initiated

H.C. Wainwright

Buy

$16

Jan-23-15

Reiterated

ROTH Capital

Buy

$29 → $23

Jul-08-14

Resumed

Oppenheimer

Perform

Feb-11-14

Initiated

Mizuho

Buy

$21

Jan-20-21 08:00AM	Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology Business Wire -10.20%
Jan-07-21 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.41%
Jan-06-21 09:13AM	Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer Business Wire
Jan-05-21 07:00AM	Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference Business Wire
Dec-29-20 08:02AM	Who Has Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares? Simply Wall St.
Dec-15-20 07:00AM	Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer Business Wire
Dec-12-20 11:18AM	Is VSTM A Good Stock To Buy Now? Insider Monkey
Dec-01-20 10:06AM	Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer Zacks
Nov-30-20 07:00AM	Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Business Wire
Nov-12-20 09:43AM	Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet? Simply Wall St. +5.59%
Nov-09-20 04:05PM	Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress Business Wire +7.38%
Oct-28-20 08:01PM	Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors Business Wire -7.26%
Oct-14-20 10:26AM	Hedge Funds Are Getting More Bullish On Verastem Inc (VSTM) Insider Monkey
Oct-08-20 08:38AM	Verastem (VSTM) Jumps: Stock Rises 7.1% Zacks
Oct-06-20 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-30-20 08:54AM	Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio Business Wire
Sep-18-20 11:50AM	How Many Verastem, Inc. (NASDAQ:VSTM) Shares Do Institutions Own? Simply Wall St.
Sep-16-20 07:00AM	Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit Business Wire
Sep-15-20 08:51AM	Is the Options Market Predicting a Spike in Verastem (VSTM) Stock? Zacks
Sep-14-20 07:00AM	Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study Business Wire +14.75%
Sep-10-20 04:05PM	Verastem Oncology to Present at Upcoming Investor Conferences Business Wire
Aug-12-20 09:43AM	Did Hedge Funds Make The Right Call On Verastem Inc (VSTM) ? Insider Monkey +6.21%
Aug-10-20 04:59PM	Why Verastem Stock Jumped Briefly This Morning Motley Fool
08:33AM	Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress Business Wire
08:30AM	Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors Business Wire
Jul-30-20 12:34PM	Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-06-20 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-23-20 11:07PM	Hedge Funds Never Loved Verastem Inc (VSTM) More Insider Monkey
Jun-22-20 04:05PM	Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma Business Wire
May-28-20 07:00AM	Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference Business Wire
May-19-20 09:47AM	Billionaire Steven Cohen Bets Big on These 3 Stocks TipRanks
May-18-20 11:20AM	Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock? Zacks
May-14-20 09:31AM	3 Biotech Stocks Under $4 That Could Surge Over 50% TipRanks
May-07-20 04:05PM	Verastem Oncology Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress Business Wire
May-04-20 03:04PM	Why Verastem Stock Is Rising Today Motley Fool +9.71%
May-01-20 11:30AM	Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year? Zacks -7.41%
Apr-27-20 12:11AM	Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I Business Wire -49.03%
Apr-23-20 08:38AM	Verastem Oncology Appoints John H. Johnson to its Board of Directors Business Wire
Apr-21-20 05:18PM	Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting Business Wire
Apr-20-20 07:00AM	Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors Business Wire +22.01%
Apr-15-20 09:30AM	Is the Options Market Predicting a Spike in Verastem (VSTM) Stock? Zacks -5.03%
Apr-13-20 06:05PM	Verastem Oncology Announces Presentation of Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors at the American Association for Cancer Research 2020 Virtual Annual Meeting I Business Wire
Apr-09-20 07:30AM	INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Verastem, Inc. for Potential Breach of Fiduciary Duty Claims. GlobeNewswire
Apr-07-20 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +10.19%
Mar-30-20 10:37AM	Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy? Zacks
Mar-19-20 11:30AM	Has Verastem (VSTM) Outpaced Other Medical Stocks This Year? Zacks +12.05%
Mar-18-20 07:01AM	Verastem Sees Hammer Chart Pattern: Time to Buy? Zacks -15.31%
Mar-11-20 04:05PM	Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results Business Wire -18.12%
Mar-10-20 09:28AM	Verastem, Inc. (VSTM) Shares March Higher, Can It Continue? Zacks
Feb-28-20 06:05AM	Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs Business Wire +46.07%
06:00AM	Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors Business Wire
Feb-05-20 11:52AM	Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-29-20 07:06AM	Verastem Oncology Announces Dosing of First Patient in CSPCs Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma Business Wire
Jan-21-20 11:14AM	Those Who Purchased Verastem (NASDAQ:VSTM) Shares Five Years Ago Have A 74% Loss To Show For It Simply Wall St. -5.79%
Jan-09-20 09:00AM	Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up Zacks
Jan-08-20 08:12AM	The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results Benzinga +36.51%
07:00AM	Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 Business Wire
Jan-06-20 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-17-19 07:03PM	Do Hedge Funds Love Verastem Inc (VSTM)? Insider Monkey -5.93%
Dec-11-19 08:46AM	Implied Volatility Surging for Verastem (VSTM) Stock Options Zacks
Dec-07-19 09:00AM	Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting Business Wire
Nov-25-19 08:57AM	Implied Volatility Surging for Verastem (VSTM) Stock Options Zacks
07:00AM	Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib) Business Wire
Nov-15-19 11:16PM	Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 07:00AM	Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award Business Wire
Nov-12-19 08:12AM	Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048 Business Wire
Nov-06-19 09:15AM	Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting Business Wire
Oct-30-19 07:01AM	The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings Benzinga -13.60%
Oct-29-19 07:35PM	Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates Zacks -6.02%
04:17PM	Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress Business Wire
Oct-23-19 07:00AM	Verastem Oncology Announces COPIKTRA (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress Business Wire +19.47%
Oct-17-19 07:00AM	Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019 Business Wire
Oct-09-19 11:18AM	Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
Oct-08-19 10:02AM	Verastem's (VSTM) Copiktra Gets Orphan Drug Designation Zacks
Oct-07-19 07:00AM	Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Business Wire
Oct-04-19 01:41PM	How Many Verastem, Inc. (NASDAQ:VSTM) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-03-19 02:25PM	Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma Business Wire +8.93%
07:00AM	Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies Business Wire
Sep-26-19 07:00AM	Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference Business Wire
Sep-20-19 01:00PM	Verastem Oncology Announces COPIKTRA (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia Business Wire
Sep-03-19 04:05PM	Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference Business Wire
Aug-06-19 08:52PM	Edited Transcript of VSTM earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 01:13PM	Verastem Inc (VSTM) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 07:25PM	Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates Zacks +6.00%
04:05PM	Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress Business Wire
Jul-30-19 07:00AM	The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings Benzinga
Jul-29-19 04:05PM	Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer Business Wire
Jul-26-19 07:26AM	The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint Benzinga +12.21%
Jul-25-19 04:05PM	Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa Business Wire
07:00AM	Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019 Business Wire
Jul-23-19 01:04PM	What Kind Of Shareholders Own Verastem, Inc. (NASDAQ:VSTM)? Simply Wall St.
Jul-03-19 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-25-19 08:53PM	Hedge Funds Have Never Been This Bullish On Verastem Inc (VSTM) Insider Monkey
Jun-24-19 08:33AM	Verastem Up on Positive Data From Early-Stage Copiktra Study Zacks
Jun-21-19 09:01AM	Verastem Shares Response Rate From COPIKTRA Data Benzinga +13.84%
07:00AM	Verastem Oncology Presents COPIKTRA (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma Business Wire
Jun-20-19 09:41AM	The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks -16.32%
07:00AM	Verastem Oncology Announces Leadership Changes Business Wire
Jun-19-19 11:20AM	Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBERICH TIMOTHY J	Director	Dec 04	Buy	2.17	50,000	108,500	218,000	Dec 07 11:15 AM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jun 25	Sale	1.91	1,161,300	2,219,941	16,142,051	Jun 29 06:29 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 27	Sale	2.31	1,301,300	3,002,099	17,303,351	Apr 29 04:30 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience